Evommune vs Roivant Sciences
EVMN and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVMN and ROIV compare
Roivant Sciences is the larger company, worth 109 times as much as Evommune ($26.7B against $244M).
Evommune keeps more of each dollar of sales as profit, with a net margin of −947% compared with −3535% at Roivant Sciences.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVMN | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $244M | $26.7B |
| Share price | $6.73 | $36.91 |
| Change, 1 year | – | 96.7% |
| Change, 5 years | – | 377% |
| Beta (5Y) | – | 0.86 |
| Employees | 48 | 721 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 24.4× (better) | 3540× |
| P/B | 0.9× (better) | 6.3× |
| FCF yield | −30.6% | −3.1% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −67.6% |
| Revenue growth, 5Y average | – | −19.1% |
| Profitability | ||
| Operating margin | −1019% (better) | −7915% |
| Net margin | −947% (better) | −3535% |
| FCF margin | −747% (better) | −10901% |
| Return on equity | −142% | −6.2% (better) |
| Return on invested capital | – | −407% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.68 | 16.72 (better) |
| Altman Z-score | 4.40 | 41.99 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.4% | 78.1% |
| Held by insiders | 51.6% | 14.3% |
| Insider net buying, 12 months | $67.9M (better) | −$870M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 16.5% | 6.3% |
Go deeper
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.